Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomics

Bevacizumab in Combination with Metronomic Chemotherapy in Patients with Anthracycline- and Taxane-Refractory Breast Cancer

(2014) J.A. García-Sáenz et al.   JOURNAL OF CHEMOTHERAPY

Sorafenib in Combination With Capecitabine: An Oral Regimen for Patients With HER2-Negative Locally Advanced or Metastatic Breast Cancer

(2012) José Baselga et al.   JOURNAL OF CLINICAL ONCOLOGY

True Patriotism: A Generation of Commitment to Quality in the Veterans Health Administration

(2012) Stephen B. Edge   JOURNAL OF CLINICAL ONCOLOGY

Contrary Effects of the Receptor Tyrosine Kinase Inhibitor Vandetanib on Constitutive and Flow-Stimulated Nitric Oxide Elaboration in Humans

(2011) Erica L. Mayer et al.   HYPERTENSION

Randomized, Placebo-Controlled, Double-Blind, Phase II Study of Axitinib Plus Docetaxel Versus Docetaxel Plus Placebo in Patients With Metastatic Breast Cancer

(2011) Hope S. Rugo et al.   JOURNAL OF CLINICAL ONCOLOGY

Normal ranges of angiogenesis regulatory proteins in human platelets

(2010) Jon E. Peterson et al.   AMERICAN JOURNAL OF HEMATOLOGY

SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer

(2010) E. L. Mayer et al.   ANNALS OF ONCOLOGY

A Double-Blind, Randomized, Placebo-Controlled, Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib (SOR) in Combination with Paclitaxel (PAC) as a First-Line Therapy in Patients (pts) with Locally Recurrent or Metastatic Breast Cancer (BC).

(2010) W. Gradishar et al.   CANCER RESEARCH

Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized Phase II study

(2010) Katalin Boér et al.   INVESTIGATIONAL NEW DRUGS

Migraine History and Breast Cancer Risk Among Postmenopausal Women

(2010) Christopher I. Li et al.   JOURNAL OF CLINICAL ONCOLOGY

Vandetanib for the Treatment of Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer

(2010) Samuel A. Wells et al.   JOURNAL OF CLINICAL ONCOLOGY

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial

(2010) Roy S Herbst et al.   LANCET ONCOLOGY

Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer

(2009) Giulia Bianchi et al.   ANTI-CANCER DRUGS

A Phase I Study of Sunitinib plus Bevacizumab in Advanced Solid Tumors

(2009) B. I. Rini et al.   CLINICAL CANCER RESEARCH

Baseline Vascular Endothelial Growth Factor Concentration as a Potential Predictive Marker of Benefit from Vandetanib in Non-Small Cell Lung Cancer

(2009) E. O. Hanrahan et al.   CLINICAL CANCER RESEARCH

Phase I/II Trial of Metronomic Chemotherapy With Daily Dalteparin and Cyclophosphamide, Twice-Weekly Methotrexate, and Daily Prednisone As Therapy for Metastatic Breast Cancer Using Vascular Endothelial Growth Factor and Soluble Vascular Endothelial Growth Factor Receptor Levels As Markers of Response

(2009) Nan Soon Wong et al.   JOURNAL OF CLINICAL ONCOLOGY

An overview of small-molecule inhibitors of VEGFR signaling

(2009) S. Percy Ivy et al.   Nature Reviews Clinical Oncology

Platelets actively sequester angiogenesis regulators

(2008) G. Lakka Klement et al.   BLOOD

Clinical biomarkers of angiogenesis inhibition

(2008) Aaron P. Brown et al.   CANCER AND METASTASIS REVIEWS

Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer

(2008) José Miguel Jurado García et al.   Clinical & Translational Oncology

Randomized Phase II Study of Vandetanib Alone or With Paclitaxel and Carboplatin as First-Line Treatment for Advanced Non–Small-Cell Lung Cancer

(2008) John V. Heymach et al.   JOURNAL OF CLINICAL ONCOLOGY

Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial of Paclitaxel Compared With Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: ECOG 2100

(2008) Bryan P. Schneider et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

(2008) Harold J. Burstein et al.   JOURNAL OF CLINICAL ONCOLOGY

Metronomic Cyclophosphamide and Capecitabine Combined With Bevacizumab in Advanced Breast Cancer

(2008) Silvia Dellapasqua et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Sorafenib in Patients With Metastatic Breast Cancer Previously Exposed to Anthracyclines or Taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336

(2008) Alvaro Moreno-Aspitia et al.   JOURNAL OF CLINICAL ONCOLOGY

Tumor Angiogenesis

(2008) Robert S. Kerbel   NEW ENGLAND JOURNAL OF MEDICINE

Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia

(2007) Agustin A. Garcia et al.   JOURNAL OF CLINICAL ONCOLOGY